Compare DSL & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DSL | EYPT |
|---|---|---|
| Founded | 2013 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2013 | 2005 |
| Metric | DSL | EYPT |
|---|---|---|
| Price | $10.99 | $13.97 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $31.80 |
| AVG Volume (30 Days) | 459.5K | ★ 1.4M |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | ★ 11.95% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,539,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $3,115.57 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.49 | $9.41 |
| 52 Week High | $12.67 | $19.11 |
| Indicator | DSL | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 56.78 | 55.34 |
| Support Level | $10.91 | $12.01 |
| Resistance Level | $11.13 | $14.52 |
| Average True Range (ATR) | 0.09 | 1.05 |
| MACD | 0.02 | 0.08 |
| Stochastic Oscillator | 79.64 | 51.38 |
DoubleLine Income Solutions Fund is a closed-end management investment company. Its primary investment objective is to seek high income and its secondary objective is to seek capital appreciation. It invests in debt securities and other income-producing investments anywhere in the world, including emerging markets. The company's investment portfolio comprises foreign corporate bonds, U.S. corporate bonds, bank loans, collateralized loan obligations, non-agency commercial mortgage backed obligations, asset-backed obligations, and municipal bonds among others.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.